TrialInvestigational new drugs2023

Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.

Markus Joerger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.